Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decline in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,807 shares, a decline of 42.4% from the September 15th total of 6,607 shares. Based on an average daily trading volume, of 63,910 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company’s shares are short sold.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Trading Down 3.9%

Shares of RGNT stock traded down $0.06 on Friday, reaching $1.49. 23,490 shares of the stock were exchanged, compared to its average volume of 63,331. The firm has a 50 day moving average of $1.90 and a two-hundred day moving average of $2.49. Regentis Biomaterials has a 1-year low of $1.23 and a 1-year high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last issued its earnings results on Friday, September 11th. The company reported ($0.22) earnings per share for the quarter.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee.

Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses.

The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology.